Merck to Acquire Verona Pharma for $10 Billion in Bid to Cushion "Patent Cliff" Impact

TradingKey

AuthorHuanyao Fang

Jul 10, 2025 9:03 AM

View all comments（0）



TradingKey - U.S. pharmaceutical giant Merck (MRK.US) has announced a roughly $10 billion deal to acquire U.K.-based biopharma firm Verona Pharma (VRNA.US), marking a major move into the respiratory disease treatment space.

Under the agreement, Merck will pay $107 per American Depositary Receipt (ADR) for Verona Pharma — a 23% premium over its previous closing price. Following the news, Verona’s shares surged 21% in pre-market trading to $104.70, Merck's stock price rose 3% at the close of trading.

Verona Pharma Stock

This acquisition ranks as Merck’s third-largest in nearly three decades and comes as the company prepares for the looming patent expiration of its blockbuster cancer drug, Keytruda. With annual sales nearing $30 billion — accounting for nearly half of Merck’s total revenue — the drug’s impending “patent cliff” in 2028 has created urgent need for new revenue sources.

The deal is expected to close by the fourth quarter of 2025. Investors are now watching closely to see whether Merck can effectively plug future revenue gaps through strategic acquisitions and establish a strong foothold in the highly competitive respiratory disease market.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Broadcom (AVGO) Stock Price Forecast: Apple’s $30B US Chip Deal Confirmed - Buy at $404?

Apple confirmed a $30B+ multiyear Broadcom chip deal for 15 billion US-made chips, including a $1.5B Colorado facility expansion. AVGO at $404, defying a broad selloff driven by Trump declaring the Iran ceasefire over

Today’s Market Recap: Micron’s U.S. Investment Expansion Ignites Chip Stocks, as SanDisk, AMD, and Broadcom Gain Collectively

TradingKey - On July 9, Eastern Time, the three major U.S. stock indices closed higher across the board, driven primarily by the technology and semiconductor sectors. As oil prices retreated from the previous session's highs, market concerns that an escalation of the U.S.-Iran conflict would fuel in

Japan and South Korea Stocks Open Strong: SoftBank Surges 7% to Lead, SK Hynix, Samsung and Kioxia All Rally Over 4%

Both the Japanese and South Korean stock markets opened sharply higher, with the Nikkei 225 and the KOSPI index continuing to surge. SoftBank soared nearly 7%, while SK Hynix, Samsung Electronics, and Kioxia all rose by over 4%.

Tesla Optimus Gen 3 Design Initially Finalized, Musk Sets Hard Target for Supply Chain: 1,000 Units Weekly Production by September.

TradingKey - According to reports from LatePost, multiple sources within Tesla's supply chain have revealed that Tesla recently issued specific procurement guidance for Optimus parts to its suppliers. The company requested that production capacity be increased to 1,000 units per week by September of this year, and further raised to between 2,000 and 2,500 units per week by the end of the year. Based on the year-end weekly capacity estimate, suppliers will have the capability to supply parts for approximately 100,000 Optimus units annually to Tesla by the end of the year.

SK Hynix Shares Surge Over 8%. U.S. IPO Draws 7-Fold Oversubscription, Can It Return to Historic Highs by the End of July?

SK Hynix's US IPO was oversubscribed, boosting its stock price; however, it is unlikely to return to its historical highs by the end of July.

Featured Tools